Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis

Author(s): Abdulla Shehab*, Akshaya S. Bhagavathula, Tamrat B. Abebe, Tadesse M. Abegaz, Asim A. Elnour, Hani M. Sabbour, Masood Uzzafer, Ahmed Hersi and Adel K. Hamad

Volume 17, Issue 4, 2019

Page: [341 - 349] Pages: 9

DOI: 10.2174/1570161116666180123111949

Price: $65

Abstract

Background: Real-world evidence from published observational studies of adherence to Novel Oral Anticoagulants (NOACs) medications and associated clinical outcome events in Atrial Fibrillation (AF) patients, was reviewed systematically.

Methods: Observational studies assessing patient adherence to NOACs conducted on AF patients between September 2010 and June 2016 were identified by systematic searching keywords to locate eligible studies, in accordance with Cochrane guidelines. PubMed, Scopus and Google Scholar databases were searched to identify the studies. Meta-analysis was performed using a random effects model with DerSimonian-Laird weighting to obtain pooled effect sizes.

Results: From 185 potentially relevant citations, 6 studies, comprising 1.6 million AF patients, were included. Among these, successful adherence to NOACs occurred in 75.6%. Adherence levels were higher in patients treated with dabigatran (72.7%) compared with those treated with apixaban (59.9%) or rivaroxaban (59.3%). However, adherence was still suboptimal (relative to an expected 80% adherence rate). Bleeding events in non-adherent patients were found to be 7.5%.

Conclusion: Suboptimal adherence to NOACs among AF patients was highlighted as a significant risk factor that may affect clinical outcomes, with a higher percentage of non-adherent patients having bleeding events. There is an urgent need for research on the effects of specific interventions to improve patient adherence to NOACs and to assess the related outcome factors that may be associated with adherence.

Keywords: Adherence, novel oral anticoagulants (NOACs), stroke, atrial fibrillation, bleeding events, vitamin K, TTR.

« Previous Next »
Graphical Abstract

[1]
Deitelzweig S, Buysman E, Pinsky B, et al. Warfarin use and stroke risk among patients with nonvalvular atrial fibrillation in a large managed care population. Clin Ther 2013; 35: 1201-10.
[2]
Rodriguez R, Carrier M, Wells P. Non-adherence to new oral anticoagulants: A reason for concern during long-term anticoagulation? J Thromb Haemost 2013; 11: 390-4.
[3]
Chatterjee S, Sardar P, Giri J, Ghosh J, Mukherjee D. Treatment discontinuations with new oral agents for long-term anticoagulation: Insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014; 89: 896-907.
[4]
Connolly S, Ezekowitz M, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
[5]
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92.
[6]
Miller C, Grandi S, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) Versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110: 453-60.
[7]
Maddox T, Ho P. Medication adherence and the patient with coronary artery disease: Challenges for the practitioner. Curr Opin Cardiol 2009; 24: 468-72.
[8]
Shore S, Carey E, Turakhia M, et al. Adherence to dabigatran and longitudinal patient outcomes: Insights from the veterans’ health administration. Am Heart J 2014; 167: 810-7.
[9]
Piccini J, Hernandez A, Zhao X, et al. Get with committee quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009; 54: 1280-9.
[10]
Kneeland PP, Fang MC. Current issues in patient adherence and persistence: Focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010; 4: 51-60.
[11]
Wang Y, Kong M, Lee L, Ng HJ, Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb Res 2014; 133: 550-4.
[12]
Ewen S, Rettig-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014; 103: 173-82.
[13]
D DiBonaventura M, Winnie W. Survey of the use of warfarin and the newer anticoagulant dabigatran in patients with atrial fibrillation. Patient Prefer Adherence 2014; 8: 167-77.
[14]
Gadó K, Kocsis E, Zelkó R, et al. Drug compliance of patients on anticoagulant treatment. Orv Hetil 2015; 156: 1281-7.
[15]
Shantha GPS, Bhave PD, Girotra S, et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes 2017; 10: e003418.
[16]
Tsadok MA, Jackevicius CA, Rahme E, Humphries KH, Pilote L. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2015; 8: 593-9.
[17]
Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and safety of non–vitamin k antagonist oral anticoagulants for atrial fibrillation and venous thromboembolism: A systematic review and meta-analyses. Clin Ther 2017; 39: 1456-78.
[18]
Nielsen PB, Skjoth F, Sogaard M, Kjaeldgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: Propensity weighted nationwide cohort study. BMJ 2017; 356: 510.
[19]
Emren SV, Şenöz O, Bilgin M, et al. Drug adherence in patients with nonvalvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey: NOAC-TR. Clin Appl Thromb Hemost 2018; 24: 525-31.
[20]
Fuster V, Ryde’n L, Cannom D, et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2011; 123: 269-7.
[21]
Jones C, Pollit V, Fitzmaurice D, Cowan C. The management of atrial fibrillation: Summary of updated NICE guidance. BMJ 2014; 348: 3655.
[22]
National Institute for Health and Clinical Excellence (NICE). NICE guidelines (CG180), atrial fibrillation (update): The management of atrial fibrillation. 2014. Available at: (http://guidance.nice.org.uk/ CG180) Accessed on December 06, 2016.
[23]
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet 2014; 383: 955-62.
[24]
Romanelli RJ, Nolting L, Dolgin M, Kym E, Orrico KB. Dabigatran versus warfarin for atrial fibrillation in real-world clinical practice: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2016; 9: 126-34.
[25]
Capranzano P, Micciche E, D’Urso L, Privitera F, Tamburino C. Personalizing oral anticoagulant treatment in patients with atrial fibrillation. Expert Rev Cardiovasc Ther 2013; 11: 959-73.
[26]
Pancholy S, Sharma P, Pancholy D, Patel T, Callans D, Marchlinski F. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol 2014; 113: 485-90.
[27]
Von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9.
[28]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 2009; 339: 2700.
[29]
Gorst-Rasmussen A, Skjoth F, Larsen T, Rasussen L, Lip G, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: A nationwide cohort study. J Thromb Haemost 2015; 13: 495-504.
[30]
Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands. Int J Clin Pharm 2015; 37: 1128-35.
[31]
Yao X, Abraham N, Alexander C, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 2016; 5: e003074.
[32]
Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the dresden non-interventional oral anticoagulation registry. Europace 2015; 17: 530-8.
[33]
Luger S, Hohmann C, Niemann D, et al. Adherence to oral anticoagulant therapy in secondary stroke prevention- impact of the novel oral anticoagulants. Patient Prefer Adherence 2015; 9: 1695-705.
[34]
Shiga T, Naganuma M, Nagao T, et al. Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese population with atrial fibrillation: A single-center observational study. J Arrhythm 2015; 31: 339-44.
[35]
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
[36]
DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: An update. Contemp Clin Trials 2007; 28: 105-14.
[37]
Haidich A. Meta-analysis in medical research. Hippokratia 2010; 14(Suppl. 1): 29-37.
[38]
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-35.
[39]
Kolandaivelu K, Leiden BB, O’Gara PT, Bhatt DL. Non-adherence to cardiovascular medications. Eur Heart J 2014; 35: 3267-76.
[40]
McHorney C, Crivera C, Laliberte F, et al. Adherence to non-vitamin K antagonist oral anticoagulant medications based on the pharmacy quality alliance measure. Curr Med Res Opin 2015; 31: 2167-73.
[41]
National Quality Measures Clearinghouse. Proportion of days covered (PDC): Percentage of patients who filled at least two prescriptions for a non-warfarin oral anticoagulant on two unique dates of service at least 180 days apart, received greater than 60 days supply of the medication, and who met the PDC threshold of 80% during the measurement period. Measure summary. July 2015. Agency for Healthcare Research and Quality. Rockville, MD. Available at: https://www.qualitymeasures.ahrq.gov/summaries/ summary/47502/proportion-of-days-covered-pdc-percentage-of-patients-whofilled-at-least-two-prescriptions-for-a-nonwarfarin-oral-anticoagulant-on-two-uniquedates-of-service-at-least-180-days-apart-received-greater-than-60-days-supply-of-themedication-and-who-met-the-pdc-t Accessed on December 10, 2016.
[42]
Brown J, Shewale A, Talbert J. Adherence to rivaroxaban, dabigatran, and apixaban for stroke prevention in incident, treatment-naïve nonvalvular atrial fibrillation. J Manag Care Spec Pharm 2016; 22: 1319-29.
[43]
Crivera C, Nelson W, Bookhart B, et al. Pharmacy quality alliance measure: Adherence to non-warfarin oral anticoagulant medications. Curr Med Res Opin 2015; 31: 1889-95.
[44]
Ewen S, Rettig-Ewen V, Mahfoud F, Bohm M, Laufs U. Drug adherence in patients taking oral anticoagulation therapy. Clin Res Cardiol 2014; 103: 173-82.
[45]
Thorne K, Jayathissa S, Dee S, et al. Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice. Intern Med J 2014; 44: 261-5.
[46]
Spivey C, Liu X, Qiao Y, et al. Stroke associated with discontinuation of warfarin therapy for atrial fibrillation. Curr Med Res Opin 2015; 31: 2021-9.
[47]
Ruff C, Giugliano R, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomized trials. Lancet 2014; 383: 955-62.
[48]
Verdecchia P, Angeli F, Aita A, Bartolini C, Reboldi G. Why switching from warfarin to NOACs? Intern Emerg Med 2016; 11: 289-93.
[49]
Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): Predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014; 63: 2141-7.
[50]
Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran the RE-LY trial. Stroke 2012; 43: 1511-7.
[51]
Bayer-Westendorf J, Pannach S. Increase of gastrointestinal bleeding with new oral anticoagulants: Problem of a meta-analysis. Gastroenterology 2013; 145: 1162-3.
[52]
Chai-Adisakspha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: A systematic review and meta-analysis. Blood 2014; 124: 2450-8.
[53]
Larsen T, Rasmussen L, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world’ patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol 2013; 61: 2264-73.
[54]
Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: Considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015; 17: 514-23.

Rights & Permissions Print Cite
Article Metrics
109
3
© 2024 Bentham Science Publishers | Privacy Policy